Home
DWTX
DWTX News

Latest DOGWOOD THERAPEUTICS INC (DWTX) News on April 24, 2025

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

GlobeNewswire

13 days ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

DWTX: Interim Data for Phase 2b Trial in 4Q25…

Zacks Small Cap Research

20 days ago

DWTX: Interim Data for Phase 2b Trial in 4Q25…

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

GlobeNewswire

21 days ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

24 days ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

MT Newswires

a month ago

Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

GlobeNewswire

a month ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…

Zacks Small Cap Research

a month ago

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…

Biotech Alert: Searches spiking for these stocks today

TipRanks

a month ago

Biotech Alert: Searches spiking for these stocks today

MT Newswires

a month ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

MT Newswires

a month ago

Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

a month ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

GlobeNewswire

a month ago

Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

GlobeNewswire

3 months ago

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

GlobeNewswire

5 months ago

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

MT Newswires

5 months ago

Top Premarket Decliners

DWTX: Phase 2 Long COVID Results Expected Soon

Zacks Small Cap Research

5 months ago

DWTX: Phase 2 Long COVID Results Expected Soon

Thomson Reuters StreetEvents

6 months ago

Q3 2024 Dogwood Therapeutics Inc Earnings Call

GuruFocus.com

6 months ago

Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ...

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

GlobeNewswire

6 months ago

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

GlobeNewswire

6 months ago

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire

6 months ago

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…

Zacks Small Cap Research

6 months ago

DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…

Share on Social Networks: